Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P. Turaga, Thoralf Lange, Kim-Hien Dao, Richard D. Press, Brian J. Druker, Giulio Superti-Furga, Michael W. Deininger

Blood (2010) 116 (17): 3278–3285.

https://doi.org/10.1182/blood-2008-10-183665

Published: 2010

Includes: Supplemental data

Journal Articles

RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients.

Jeffrey W. Tyner, PhD, Stephanie Willis, BS, Michael W.N. Deininger, MD, PhD, Brian J. Druker, MD

Blood (2007) 110 (11): 208.

https://doi.org/10.1182/blood.V110.11.208.208

Published: 2007

Journal Articles

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

Daniel W. Sherbenou, BA, Oliver J. Hantschel, PhD, Lalita Turaga, BS, Ines Kaupe Mag, Stephanie Willis, BS, Thomas Bumm, MD, Richard D. Press, MD, PhD, Giulio Superti-Furga, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2007) 110 (11): 2936.

https://doi.org/10.1182/blood.V110.11.2936.2936

Published: 2007

Journal Articles

A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression.

Daniel W. Sherbenou, BA, Oliver Hantschel, PhD, Stephanie Willis, BS, Richard D. Press, MD, Brian J. Druker, MD, Giulio Superti-Furga, PhD, Michael W. Deininger, MD, PhD

Blood (2006) 108 (11): 2188.

https://doi.org/10.1182/blood.V108.11.2188.2188

Published: 2006

Journal Articles

A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.

Richard D. Press, MD, PhD, Stephanie Willis, Carole Rempfer, Michael J. Mauro, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD

Blood (2006) 108 (11): 2152.

https://doi.org/10.1182/blood.V108.11.2152.2152

Published: 2006

Journal Articles

Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib.

Lucy Crossman, Michael Heinrich, Richard Press, Stephanie Willis, Michael Deininger, Brian Druker

Blood (2004) 104 (11): 2091.

https://doi.org/10.1182/blood.V104.11.2091.2091

Published: 2004

Journal Articles

Detection of Imatinib-Resistant BCR-ABL Mutants in Drug-Naïve Patients: Correlation with Disease Phase and Clonal Evolution but Not with Response to Treatment.

Michael W. Deininger, MD, PhD, Stephanie Willis, Thoralf Lange, MD, Shannon McWeeney, PhD, Sandra Otto, Brian J. Druker, MD

Blood (2004) 104 (11): 273.

https://doi.org/10.1182/blood.V104.11.273.273

Published: 2004

Journal Articles

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines

Paul La Rosée, Kara Johnson, Amie S. Corbin, Eric P. Stoffregen, Erika M. Moseson, Stephanie Willis, Michael M. Mauro, Junia V. Melo, Michael W. Deininger, Brian J. Druker

Blood (2004) 103 (1): 208–215.

https://doi.org/10.1182/blood-2003-04-1074

Published: 2004

NARROW

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients.

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression.

A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.

Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib.

Detection of Imatinib-Resistant BCR-ABL Mutants in Drug-Naïve Patients: Correlation with Disease Phase and Clonal Evolution but Not with Response to Treatment.

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only